Brickell Biotech, Inc. (BBI)
Dopo ore:
| Chiusura precedente | 3,2700 |
| Aperto | 3,3400 |
| Denaro | 3,2900 x 3200 |
| Lettera | 3,4200 x 900 |
| Min-Max giorno | 3,2100 - 3,4200 |
| Intervallo di 52 settimane | 2,8800 - 37,3500 |
| Volume | |
| Media Volume | 270.884 |
| Capitalizzazione | 8,916M |
| Beta (5 anni mensile) | 0,08 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,4200 |
| Prossima data utili | 07 nov 2022 - 11 nov 2022 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 48,75 |
- GlobeNewswire
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developin
- GlobeNewswire
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell’s management will host a conference call and webcast at 4:30 p.m.
- GlobeNewswire
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement
BOULDER, Colo., July 20, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it received formal notice from The Nasdaq Stock Market (“Nasdaq”) stating that Brickell has regained compliance with the minimum bid price requirement f
